The Department of Veterans Affairs launched a clinical trial of semaglutide as a potential treatment for alcohol use disorder in veterans on July 30. The condition affects an estimated 400,000 former service members. Semaglutide is the active ingredient in the weight-loss and diabetes drugs Ozempic and Wegovy. The VA trial

The Department of Veterans Affairs launched a clinical trial of semaglutide to treat alcohol use disorder in veterans on July 30, testing whether the active ingredient in blockbuster weight-loss drugs Wegovy and Ozempic can also combat addiction. Veterans experience disproportionately high rates of alcohol use disorder compared to the general

The Department of Veterans Affairs on July 30 announced a new clinical trial to evaluate semaglutide — the active ingredient in Ozempic and Wegovy — as a treatment for alcohol use disorder among veterans, the first such trial within the nation’s largest integrated health system. Alcohol use disorder is among

The Department of Veterans Affairs reported in early August that its pending backlog of disability compensation and pension claims had fallen below 70,000 for the first time since February 2020, marking a milestone in the nation’s largest integrated benefits system. The backlog — defined as claims pending beyond 125 days

The Department of Veterans Affairs has launched a clinical trial evaluating semaglutide — the active ingredient in Ozempic and Wegovy — as a potential treatment for alcohol use disorder, the agency announced July 30. It is the first such trial within the VA healthcare system. Emerging research suggests GLP-1 receptor